Alzheimer’s Disease (AD) is a complex neurodegenerative disease that is characterized by the accumulation of amyloid-beta (Aβ) peptides in the brain. It is the most common type of dementia which begins with mild memory loss and leads to severe decline in one’s ability to hold adequate conversation and response with the environment. β-secretase-1(BACE-1) is a key enzyme involved in the production of Aβ peptides, making it an attractive target for drug discovery in AD treatment. Herein, this study aimed to investigate the anti-alzheimer’s potential of selected bioactive compounds against BACE-1 protein. Molecular docking was employed using Pyrx and Biovia discovery studio software to predict potential selected bioactive antagonists and non-covalent interactions between the selected ligands, standard drugs and the target protein. BACE-1 target protein was docked with ligands namely; Tacrine, Harmine, Coumarin, Berberine, Indole, Resveratrol, Huperzine, 3-chloro-R(2),C(6)-bis(4-fluorophenyl)-3- methylpipiridin-4-one (CFMP), and the standard alzheimer’s drugs namely; Donepezil and Galantamine after which the ligand with the best binding affinity was determined. The docking result from this study revealed Resveratrol as the ligand with the best binding affinity when docked with the selected Alzheimer’s target proteins.
Select your language of interest to view the total content in your interested language